4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Arvinas, Inc. (ARVN) operates in the Biotechnology industry and is headquartered in New Haven, United States with about 246 employees. Its market capitalization is roughly $518 million. In the fiscal year ended 2025-12-31, ARVN reported $263M in revenue and ($81M) in net income.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Interactive charts & full statements → Open the ARVN valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $263M | $263M | $78M | $131M | — |
| Operating Income (EBIT) | ($118M) | ($250M) | ($402M) | ($263M) | — |
| Net Income | ($81M) | ($199M) | ($367M) | ($282M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $16M | $10M | $42M | $22M | $189M | — |
| Operating Income (EBIT) | ($64M) | ($75M) | ($44M) | ($72M) | $71M | — |
| Net Income | ($58M) | ($67M) | ($35M) | ($61M) | $83M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $718M | $1.1B | $1.3B | $1.3B | — |
| Total Liabilities | $284M | $530M | $645M | $704M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ARVN viewer.
About TickerBase · Data methodology & sources